Dr. Walko has received honoraria from Bristol-Myers Squibb and Merck. Dr. Millis is an employee of Foundation Medicine. The other authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
StillerCATramaABrewsterDH. Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE project. Cancer Epidemiol2014;38:670–678.
Regnier-RosencherEGuillotBDupinN. Treatments for classic Kaposi sarcoma: a systematic review of the literature. J Am Acad Dermatol2013;68:313–331.
Di LorenzoGKreuterADi TrolioR. Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi's sarcoma: a multicenter study. J Invest Dermatol2008;128:1578–1580.
PaydasSBagirEKDeveciMAGonlusenG. Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas. Med Oncol2016;33:93.
Beldi-FerchiouALambertMDogniauxS. PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. Oncotarget2016;7:72961–72977.
GoodmanAMKatoSBazhenovaL. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther2017;16:2598–2608.
JohnsonDBFramptonGMRiothMJ. Targeted next generation sequencing identifies markers of response to PD-1 blockade. Cancer Immunol Res2016;4:959–967.
FramptonGMFichtenholtzAOttoGA. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol2013;31:1023–1031.
LiuZFangQZuoJ. Global epidemiology of human herpesvirus 8 in men who have sex with men: a systematic review and meta-analysis. J Med Virol2018;90:582–591.
RoyseKEEl ChaerFAmirianES. Disparities in Kaposi sarcoma incidence and survival in the United States: 2000-2013. PLoS One2017;12:e0182750.